Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neurochem Int
2014 Jul 01;73:98-106. doi: 10.1016/j.neuint.2013.10.009.
Show Gene links
Show Anatomy links
Stereoselective inhibition of serotonin transporters by antimalarial compounds.
Beckman ML, Pramod AB, Perley D, Henry LK.
???displayArticle.abstract???
The serotonin (5-HT) transporter (SERT) is an integral membrane protein that functions to reuptake 5-HT released into the synapse following neurotransmission. This role serves an important regulatory mechanism in neuronal homeostasis. Previous studies have demonstrated that several clinically important antimalarial compounds inhibit serotonin (5-hydroxytryptamine, 5-HT) reuptake. In this study, we examined the details of antimalarial inhibition of 5-HT transport in both Drosophila (dSERT) and human SERT (hSERT) using electrophysiologic, biochemical and computational approaches. We found that the cinchona alkaloids quinidine and cinchonine, which have identical stereochemistry about carbons 8 and 9, exhibited the greatest inhibition of dSERT and hSERT transporter function whereas quinine and cinchonidine, enantiomers of quinidine and cinchonine, respectively, were weaker inhibitors of dSERT and hSERT. Furthermore, SERT mutations known to decrease the binding affinity of many antidepressants affected the cinchona alkaloids in a stereo-specific manner where the similar inhibitory profiles for quinine and cinchonidine (8S,9R) were distinct from quinidine and cinchonine (8R,9S). Small molecule docking studies with hSERT homology models predict that quinine and cinchonidine bind to the central 5-HT binding site (S1) whereas quinidine and cinchonine bind to the S2 site. Taken together, the data presented here support binding of cinchona alkaloids to two different sites on SERT defined by their stereochemistry which implies separate modes of transporter inhibition. Notably, the most potent antimalarial inhibitors of SERT appear to preferentially bind to the S2 site. Our findings provide important insight related to how this class of drugs can modulate the serotonergic system as well as identify compounds that may discriminate between the S1 and S2 binding sites and serve as lead compounds for novel SERT inhibitors.
???displayArticle.pubmedLink???
24161619 ???displayArticle.pmcLink???PMC5553891 ???displayArticle.link???Neurochem Int ???displayArticle.grants???[+]
Andersen,
Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants.
2009, Pubmed
Andersen,
Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants.
2009,
Pubmed Barker,
High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol.
1998,
Pubmed Beckman,
Substrates and temperature differentiate ion flux from serotonin flux in a serotonin transporter.
2001,
Pubmed
,
Xenbase Berry,
Analysis of antiarrhythmic drug concentrations determined during electrophysiologic drug testing in patients with inducible tachycardias.
1988,
Pubmed Beuming,
A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function.
2006,
Pubmed Blakely,
Cloning and expression of a functional serotonin transporter from rat brain.
1991,
Pubmed Bridges,
Effect of quinidine and related compounds on uptake and release of serotonin by blood platelets.
1966,
Pubmed Bröer,
The solute carrier 6 family of transporters.
2012,
Pubmed Chang,
Cloning and expression of the mouse serotonin transporter.
1996,
Pubmed Chen,
The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding.
1997,
Pubmed Chen,
Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception.
1998,
Pubmed Clement,
Investigation of the presynaptic effects of quinine and quinidine on the release and uptake of monoamines in rat brain tissue.
1998,
Pubmed Combs,
Small-molecule ligand docking into comparative models with Rosetta.
2013,
Pubmed Combs,
Y95 and E444 interaction required for high-affinity S-citalopram binding in the human serotonin transporter.
2011,
Pubmed Corey,
A cocaine-sensitive Drosophila serotonin transporter: cloning, expression, and electrophysiological characterization.
1994,
Pubmed
,
Xenbase Davis,
The effect of quinidine on the uptake and release of serotonin by platelets in vitro.
1969,
Pubmed Dean,
2C or not 2C: phenethylamine designer drug review.
2013,
Pubmed Demchyshyn,
Cloning, expression, and localization of a chloride-facilitated, cocaine-sensitive serotonin transporter from Drosophila melanogaster.
1994,
Pubmed Di Costanzo,
Does abnormal neuronal excitability exist in myotonic dystrophy? II. Effects of the antiarrhythmic drug hydroquinidine on apathy and hypersomnia.
2000,
Pubmed Fuller,
Serotonin uptake and serotonin uptake inhibition.
1990,
Pubmed Galli,
Drosophila serotonin transporters have voltage-dependent uptake coupled to a serotonin-gated ion channel.
1997,
Pubmed
,
Xenbase Guo,
The additive effects of quinine on antidepressant drugs in the forced swimming test in mice.
1995,
Pubmed Hahn,
A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters.
2003,
Pubmed Hawkins,
Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database.
2010,
Pubmed Henry,
A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport.
2011,
Pubmed
,
Xenbase Henry,
Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants.
2006,
Pubmed Hoffman,
Cloning of a serotonin transporter affected by antidepressants.
1991,
Pubmed Kantcheva,
Chloride binding site of neurotransmitter sodium symporters.
2013,
Pubmed Kaufmann,
Using RosettaLigand for small molecule docking into comparative models.
2012,
Pubmed Kaufmann,
Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies.
2009,
Pubmed Kristensen,
SLC6 neurotransmitter transporters: structure, function, and regulation.
2011,
Pubmed Kuhlman,
Design of a novel globular protein fold with atomic-level accuracy.
2003,
Pubmed Leaver-Fay,
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules.
2011,
Pubmed Lin,
Single-channel currents produced by the serotonin transporter and analysis of a mutation affecting ion permeation.
1996,
Pubmed
,
Xenbase Mager,
Conducting states of a mammalian serotonin transporter.
1994,
Pubmed
,
Xenbase Mandell,
Sub-angstrom accuracy in protein loop reconstruction by robotics-inspired conformational sampling.
2009,
Pubmed Notterman,
Stereoselective renal tubular secretion of quinidine and quinine.
1986,
Pubmed Oleksyn,
Molecular properties of Cinchona alkaloids: a theoretical approach.
1992,
Pubmed Oz,
Methylene blue inhibits function of the 5-HT transporter.
2012,
Pubmed Petersen,
Ionic interactions in the Drosophila serotonin transporter identify it as a serotonin channel.
1999,
Pubmed
,
Xenbase Piscitelli,
Neurotransmitter/sodium symporter orthologue LeuT has a single high-affinity substrate site.
2010,
Pubmed Plenge,
Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter.
2012,
Pubmed Plenge,
Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites.
2007,
Pubmed Pramod,
SLC6 transporters: structure, function, regulation, disease association and therapeutics.
2013,
Pubmed Pussard,
Quinine disposition in globally malnourished children with cerebral malaria.
1999,
Pubmed Quick,
Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation.
2009,
Pubmed Ramamoorthy,
Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.
1993,
Pubmed Rudnick,
The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.
1992,
Pubmed Singh,
A competitive inhibitor traps LeuT in an open-to-out conformation.
2008,
Pubmed Singh,
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
2007,
Pubmed Thompson,
Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.
2011,
Pubmed Volkow,
Drug addiction: the neurobiology of behaviour gone awry.
2004,
Pubmed Wang,
The effects of rubidium, caesium and quinine on 5-HT-mediated behaviour in rat and mouse--3. Quinine.
1992,
Pubmed White,
Clinical pharmacokinetics of antimalarial drugs.
1985,
Pubmed Yamashita,
Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters.
2005,
Pubmed Yu,
Two mechanisms of ion selectivity in protein binding sites.
2010,
Pubmed Zhou,
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
2007,
Pubmed Zhou,
Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures.
2009,
Pubmed
